ПОЛУЧЕНИЕ НАНОРАЗМЕРНЫХ СИСТЕМ ДЛЯ СО-ДОСТАВКИ ПАКЛИТАКСЕЛА И ПРОИЗВОДНОГО ЭТОПОЗИДА НА ОСНОВЕ АЛЬБУМИНА И СОПОЛИМЕРОВ МОЛОЧНОЙ И ГЛИКОЛЕВОЙ КИСЛОТ И СРАВНИТЕЛЬНАЯ ОЦЕНКА ИХ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ НА ЛИНИИ КЛЕТОК МЫШИНОЙ ГЛИОМЫ GL261

1. Sung H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // A Cancer Journal of Clinicians. 2021; 71(3): 209-249.

2. Zeinali M. et al. Nanovehicles for co-delivery of anticancer agents //Drug Discovery Today. -2020.

3. Pan J. et al. Polymeric co-delivery systems in cancer treatment: An overview on component drugs' dosage ratio effect //Molecules. 2019; 24(6):1035.

4. Afsharzadeh M. et al. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment //Artificial cells, nanomedicine, and biotechnology. 2018; 46(6.): 1095-1110.

5. Maleki H. et al. Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma //International journal of pharmaceutics. 2021; 604:120722.

6. Wang B. et al. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma //Journal of nanobiotechnology. 2015; 13(1):1-11.

7. Duan R. et al. Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma //Colloids and surfaces b: biointerfaces. 2017; 159: 880-887.

8. Huang T. et al. Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide //Molecular medicine reports. 2012; 6(5):1013-1017.

9. Weaver B.A. How Taxol/paclitaxel kills cancer cells // Mol Biol Cell. 2014; 25(18): P.2677-2681.

10. Montecucco A. et al. Molecular mechanisms of etoposide // EXCLI Journal. 2015; (14): 95-108.

11. Xu Y. et al. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells // Oncotarget. 2016; 7(15): 20890.

12. Luiz M.T. et al. Highlights in targeted nanoparticles as a delivery strategy for glioma treatment //International Journal of Pharmaceutics. 2021; 120758.

13. Ohnuma T. et al. Preparation and Antitumor Activity of 2" -O-, 3" -O-and 2", 3" -Di-O-substituted Derivatives of Etoposide //Chemical and pharmaceutical bulletin. 1992; 40(7): 1783-1788.

14. Neil I. Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor-derived SPARC for targeting //Drug Deliv. Rep. 2007; 37-41.

15. Kumskova N. et al. How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release //Journal of microencapsulation. 2020; 37(3): 283-295.

16. Leu Y.L. et al. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin- based anticancer therapy //Journal of medicinal chemistry. 2008; 51(6): 1740-1746.

17. Maleki H. et al. Preparation of Paclitaxel and Etoposide Co-loaded mPEG-PLGA Nanoparticles: an Investigation with Artificial Neural Network //Journal of Pharmaceutical Innovation. 2019; 1-15.